CompletedPhase 4NCT03910621
Safety and Efficacy of Miglustat in Chinese NPC Patients
Studying Niemann-Pick disease type C
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Actelion
- Principal Investigator
- Yue WuJanssen China R&D
- Intervention
- Miglustat(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2020 – 2022
Study locations (2)
- Peking University first Hospital, Beijing, China
- Xin Hua Hospital, Shanghai Jiao Tong University, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03910621 on ClinicalTrials.govOther trials for Niemann-Pick disease type C
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05588167Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type CEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- RECRUITINGPHASE3NCT05163288A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type CIntraBio Inc
- ACTIVE NOT RECRUITINGPHASE3NCT04860960Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1Cyclo Therapeutics, Inc.
- RECRUITINGNANCT00344331Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type CEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)